Daniel P. Petrylak, MD, presented “Novel Targeted Therapies” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Petrylak, Daniel P. “Novel Targeted Therapies.” October 8, 2024. Accessed Apr 2026. https://grandroundsinurology.com/novel-targeted-therapies/
Novel Targeted Therapies – Summary
Daniel P. Petrylak, MD, presents a detailed 9-minute discussion on novel targeted therapies for prostate cancer. The discussion focuses on the challenges and advances in addressing androgen receptor (AR) mutations and resistance mechanisms in castration-resistant prostate cancer (CRPC). The AR’s central role in disease progression is underscored, and resistance pathways are addressed.
Dr. Petrylak introduces PROTAC (proteolysis-targeting chimera) technology as a promising solution for targeting AR resistance. Early clinical trials of PROTAC ARV-110 demonstrated its effectiveness. The development of ARV-766, a next-generation PROTAC, broadens the therapeutic scope by targeting additional AR mutations and showing improved outcomes in preliminary trials. ARV-766 is now progressing to phase III trials, representing a promising step forward in personalized prostate cancer treatment.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, is a Professor of Medicine, specializing in Medical Oncology and Urology, and Chief of Genitourinary Oncology at Yale University Cancer Center in New Haven, Connecticut. Dr. Petrylak is an internationally renowned medical oncologist and is considered a pioneer in the research and development of new drugs and treatments to fight cancers of the prostate, bladder, and kidney.
